Are you over 18 and want to see adult content?
More Annotations
![A complete backup of guyanatimesgy.com](https://www.archivebay.com/archive2/a7eabe68-d99b-4984-90bc-5217c07db6fc.png)
A complete backup of guyanatimesgy.com
Are you over 18 and want to see adult content?
![A complete backup of yarollerschool.com.ua](https://www.archivebay.com/archive2/52517bbd-15f1-4638-8f1b-06c008fd05d9.png)
A complete backup of yarollerschool.com.ua
Are you over 18 and want to see adult content?
![A complete backup of mornaturalforums.ru](https://www.archivebay.com/archive2/7ba3d4f9-b169-49e1-a484-db415e5260b8.png)
A complete backup of mornaturalforums.ru
Are you over 18 and want to see adult content?
![A complete backup of cascadeblues.org](https://www.archivebay.com/archive2/42f7df60-a4e1-46bc-884e-73d257d6d15a.png)
A complete backup of cascadeblues.org
Are you over 18 and want to see adult content?
![A complete backup of dossieroutpost.com](https://www.archivebay.com/archive2/e91a43d3-84b6-407a-8288-7038398b9cec.png)
A complete backup of dossieroutpost.com
Are you over 18 and want to see adult content?
![A complete backup of contrastplug.site](https://www.archivebay.com/archive2/8ef045d9-1a7e-465c-8531-e06e1791a7da.png)
A complete backup of contrastplug.site
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of www.sport.pl/F1/7](https://www.archivebay.com/archive2/3d429b3b-1968-46bb-8c5f-b09787d27236.png)
A complete backup of www.sport.pl/F1/7
Are you over 18 and want to see adult content?
![A complete backup of sports.ndtv.com/english-premier-league/chelsea-vs-man-united-anthony-martial-harry-maguire-on-target-as-man](https://www.archivebay.com/archive2/3d88c4dc-f83a-42d8-a74c-df04a29280df.png)
A complete backup of sports.ndtv.com/english-premier-league/chelsea-vs-man-united-anthony-martial-harry-maguire-on-target-as-man
Are you over 18 and want to see adult content?
![A complete backup of www.latestly.com/india/education/maharashtra-hsc-board-exam-2020-begins-from-today-nearly-15-lakh-students-](https://www.archivebay.com/archive2/a28b01b5-67c4-4035-be5a-eaa008a48c9e.png)
A complete backup of www.latestly.com/india/education/maharashtra-hsc-board-exam-2020-begins-from-today-nearly-15-lakh-students-
Are you over 18 and want to see adult content?
Text
TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.CONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map > RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to considerHARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
NICK BEIM - VENROCK
Nick Beim focuses primarily on artificial intelligence, software, fintech and defense investments. He blogs on the economics of innovation at www.nickbeim.com. Nick’s current investments include Dataminr, a real-time AI platform that identifies critical breaking information from publicly available data sets; Interos, a multi-tier, multi-factor third-party risk management platform; RebellionLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
ETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company. HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.CONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map > RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to considerHARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
NICK BEIM - VENROCK
Nick Beim focuses primarily on artificial intelligence, software, fintech and defense investments. He blogs on the economics of innovation at www.nickbeim.com. Nick’s current investments include Dataminr, a real-time AI platform that identifies critical breaking information from publicly available data sets; Interos, a multi-tier, multi-factor third-party risk management platform; RebellionLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
ETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ABOUT VENROCK
In the 1930’s, Laurance Rockefeller (1910-2004) pioneered early-stage venture capital in the United States by investing in Eddie Rickenbacker and James “Mac” McDonnell, the entrepreneurs behind Eastern Airlines and McDonnell Aircraft. Laurance was the fourth of six children of John D. Rockefeller, Jr. Over the next 20 years, he became well known as an investorCONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map >THE CRYPTO MISSION
The Crypto Mission. 4.6.2018. by David Pakman. In 1998, the United States Department of Justice filed an antitrust complaint against Microsoft, accusing the company of abusing their monopoly power. Among the litany of examples, one of the most egregious was Microsoft’s Windows licensing policy whereby computer makers who shipped Windowspre
BRYAN ROBERTS
Bryan joined Venrock in 1997. He is based in Palo Alto and seeks to partner with early-stage entrepreneurs innovating across the healthcare and life sciences industries. Bryan is currently involved with several companies across therapeutics, genomics, and HCIT, including 10X Genomics, Devoted Health, Element Biosciences, Encoded Therapeutics, Grand Rounds, and Lyra Health. Past investmentsANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior toSTEVE GOLDBY
Steve joined Venrock in 2007 after spending nine years as CEO of Venrock-backed materials science company Symyx Technologies. He serves on the Board of Directors of Nanosys and Phononic Devices. Previously, he served on the Boards of Affymax (acquired by GlaxoSmithKline), Aspect Development (acquired by i2 Technologies), Ilypsa (acquired by Amgen), Intermolecular, One Touch Systems INCENTIVES AND INFORMATION DRIVE HEALTH CARE INNOVATION Incentives and information drive health care innovation: lessons from Medicare Advantage. This article first appeared in statnews.com. It is co-authored with Bryan Roberts. Health care in America often feels like it moves at a glacial pace, if that fast. Case in point: fax machines remain indispensable as a way of transferring information. TONY EVNIN - VENROCK Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by JohnsonNIMISH SHAH
Nimish Shah joined Venrock’s New York office in 2013 and focuses on a range of healthcare subsectors including generics, specialty pharmaceuticals, biotechnology and animal health. Most recently, he worked at Citadel and was involved in the firm’s healthcare investments. Prior to Citadel, Nimish was a Research Analyst at CreditSuisse
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation of HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior toNICK BEIM - VENROCK
Nick Beim focuses primarily on artificial intelligence, software, fintech and defense investments. He blogs on the economics of innovation at www.nickbeim.com. Nick’s current investments include Dataminr, a real-time AI platform that identifies critical breaking information from publicly available data sets; Interos, a multi-tier, multi-factor third-party risk management platform; RebellionLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
ETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior toNICK BEIM - VENROCK
Nick Beim focuses primarily on artificial intelligence, software, fintech and defense investments. He blogs on the economics of innovation at www.nickbeim.com. Nick’s current investments include Dataminr, a real-time AI platform that identifies critical breaking information from publicly available data sets; Interos, a multi-tier, multi-factor third-party risk management platform; RebellionLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
ETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up. RUNNING THROUGH WALLS: A VENROCK PODCAST FEATURING CANDID Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969. RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider JULIE PARK - VENROCK Julie joined Venrock in 2020 and focuses on investments in the consumer, commerce, and SMB tools & services sectors. Most recently, Julie was an executive at Facebook, where she helped SMBs grow as director of the global long tail ads business. Prior, she was on the founding product and sales teams at Pinterest. Before moving INCENTIVES AND INFORMATION DRIVE HEALTH CARE INNOVATION Incentives and information drive health care innovation: lessons from Medicare Advantage. This article first appeared in statnews.com. It is co-authored with Bryan Roberts. Health care in America often feels like it moves at a glacial pace, if that fast. Case in point: fax machines remain indispensable as a way of transferring information.NICK BEIM - VENROCK
Nick Beim focuses primarily on artificial intelligence, software, fintech and defense investments. He blogs on the economics of innovation at www.nickbeim.com. Nick’s current investments include Dataminr, a real-time AI platform that identifies critical breaking information from publicly available data sets; Interos, a multi-tier, multi-factor third-party risk management platform; Rebellion TONY EVNIN - VENROCK Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by JohnsonNIMISH SHAH
Nimish Shah joined Venrock’s New York office in 2013 and focuses on a range of healthcare subsectors including generics, specialty pharmaceuticals, biotechnology and animal health. Most recently, he worked at Citadel and was involved in the firm’s healthcare investments. Prior to Citadel, Nimish was a Research Analyst at CreditSuisse
SHARAH MARWAH
Sharah joined Venrock in 2017 as Head of Talent. She focuses on talent strategy for both the firm and portfolio companies. Previously, Sharah was the Director of Recruiting at One Medical, a business focused on transforming healthcare technology, delivery and experience in primary care. There, she built, scaled and led the team responsible forrecruiting
KOLE ROYBAL
Dr. Roybal is an Assistant Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He received his doctorate in Immunology from UT Southwestern Medical Center and was a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of Wendell A. Lim at UCSF and the Howard HughesMedical
HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation of HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aBOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.LISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation ofNEWS - VENROCK
Venrock Extends Leading Healthcare IT Franchise, Adds Robert Kocher. Download PDF 5.27.2011. Venrock Raises $350 Million Diversified Venture Fund. Download PDF 7.6.2010. Venrock’s Anthony Evnin Receives NVCA Lifetime Achievement Award. Download PDF 4.30.2009. Venrock Raises $194 Million for Healthcare Growth Fund. Download PDF3.4.2009.
CONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map > RUNNING THROUGH WALLS: A VENROCK PODCAST FEATURING CANDID Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969. RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider HERE COMES DIGITAL SPORTS COLLECTIBLES* Here Comes Digital Sports Collectibles* - Venrock. 8.6.2020. by David Pakman. *on a blockchain! Dapper Labs, in partnership with the NBA and the NBPA has launched the beta of their NBA TopShot crypto-collectible game. The first part of the experience allows consumers to buy packs of compelling NBA game moments.MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over a INCENTIVES AND INFORMATION DRIVE HEALTH CARE INNOVATION Incentives and information drive health care innovation: lessons from Medicare Advantage. This article first appeared in statnews.com. It is co-authored with Bryan Roberts. Health care in America often feels like it moves at a glacial pace, if that fast. Case in point: fax machines remain indispensable as a way of transferring information. TONY EVNIN - VENROCK Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by JohnsonETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
NIMISH SHAH
Nimish Shah joined Venrock’s New York office in 2013 and focuses on a range of healthcare subsectors including generics, specialty pharmaceuticals, biotechnology and animal health. Most recently, he worked at Citadel and was involved in the firm’s healthcare investments. Prior to Citadel, Nimish was a Research Analyst at CreditSuisse
HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation of HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems. View Portfolio.TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Nightfall AI does both. On the one hand, Nightfall (formerly known as Watchtower) is the next generation of DLP (Data Loss Prevention), which helps enterprises to detect and prevent data breaches, such as from insider threats–either intentional or inadvertent. DLPs can stop data exfiltration and help identify sensitive data that shows upin
MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation ofNEWS - VENROCK
Venrock Extends Leading Healthcare IT Franchise, Adds Robert Kocher. Download PDF 5.27.2011. Venrock Raises $350 Million Diversified Venture Fund. Download PDF 7.6.2010. Venrock’s Anthony Evnin Receives NVCA Lifetime Achievement Award. Download PDF 4.30.2009. Venrock Raises $194 Million for Healthcare Growth Fund. Download PDF3.4.2009.
CONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map > RUNNING THROUGH WALLS: A VENROCK PODCAST FEATURING CANDID Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969. RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider HERE COMES DIGITAL SPORTS COLLECTIBLES* Here Comes Digital Sports Collectibles* - Venrock. 8.6.2020. by David Pakman. *on a blockchain! Dapper Labs, in partnership with the NBA and the NBPA has launched the beta of their NBA TopShot crypto-collectible game. The first part of the experience allows consumers to buy packs of compelling NBA game moments.MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over a INCENTIVES AND INFORMATION DRIVE HEALTH CARE INNOVATION Incentives and information drive health care innovation: lessons from Medicare Advantage. This article first appeared in statnews.com. It is co-authored with Bryan Roberts. Health care in America often feels like it moves at a glacial pace, if that fast. Case in point: fax machines remain indispensable as a way of transferring information. TONY EVNIN - VENROCK Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by JohnsonETHAN BATRASKI
Ethan Batraski. Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, AtomComputing
NIMISH SHAH
Nimish Shah joined Venrock’s New York office in 2013 and focuses on a range of healthcare subsectors including generics, specialty pharmaceuticals, biotechnology and animal health. Most recently, he worked at Citadel and was involved in the firm’s healthcare investments. Prior to Citadel, Nimish was a Research Analyst at CreditSuisse
HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT “Venrock has passion for solving big problems, respect for entrepreneurs, and deep empathy for the process of company building. They are not just our investors, they are our partners every step ofthe way.
TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Four years ago I met a recent Stanford grad named Isaac Madan.He had an impressive computer science background, had founded a startup in college, and was interested in venture capital.MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation of HOME - VENROCKPORTFOLIOTEAMINSIGHTSNEWSABOUTCONTACT “Venrock has passion for solving big problems, respect for entrepreneurs, and deep empathy for the process of company building. They are not just our investors, they are our partners every step ofthe way.
TEAM - VENROCK
“Everyone is a friend when things are going well. Venrock is just as steadfast when we hit those unexpected bumps – they really roll up their sleeves and partner up.HARRY BARBER
Harry Barber focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Harry earned his MBA in Healthcare Management from the Wharton School, where he was a Thouron Scholar. During his time at Wharton, Harry completed a placement at Spark Therapeutics and an internship with the Boston Consulting Group. Priorto business
WHY I FELL FOR NIGHTFALL AI Four years ago I met a recent Stanford grad named Isaac Madan.He had an impressive computer science background, had founded a startup in college, and was interested in venture capital.MARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aLISA HARRIS
Lisa joined Venrock as Chief Financial Officer in January 2012, and leads Venrock’s Finance team, which is responsible for the financial reporting of the firm’s investment funds as well as the day-to-day management of firm-wide finance and accounting matters. In addition, Lisa is responsible for investor relations and LP reporting, and worksclosely with our
BOB KOCHER, MD
Bob Kocher, MD is a Partner at Venrock and focuses on healthcare IT and services investments. He currently serves on the Boards of Devoted Health, Virta Health, Aledade, Lyra Health, Newco Health, Sitka, and Premera Blue Cross. He is a Board Observer at Grand Rounds, Stride, Doctor on Demand, Suki, and The Public Health Company.ANDREW GOTTESDIENER
Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to PAUL DOSSA - VENROCK Paul joined the public investment healthcare team at Venrock in 2015. He analyzes biotech and pharmaceutical companies over a large range of therapeutic areas. He was previously part of the research team at LifeSci Advisors, writing initiation reports for early-stage biotech companies. Prior to becoming part of the investment community, he wasa graduate student
DAVID STEPP
David is responsible for overseeing the operations and administration of the firm. David also serves as Chief Compliance Officer and General Counsel, managing the firm’s regulatory, legal, and compliance programs. David joined Venrock in 2007 from Cooley LLP, where his practice focused on the formation and representation of venture capital partnerships and the representation ofNEWS - VENROCK
See the Pitch Deck that an Ex-Goldman Partner and a Public-Health Doctor Used to Convince Verily and Venrock to Pour $8 Million into a Startup Taking a New Approach to Fighting Disease OutbreaksCONTACT - VENROCK
Boston. 34 Farnsworth St, 3rd Floor, Boston, MA 02210 — Phone 617.995.2000 Fax 617.995.2001 — View Map > RUNNING THROUGH WALLS: A VENROCK PODCAST FEATURING CANDID Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969. RUNNING THROUGH WALLS: NAVIGATING THE IPO PROCESS Venrock partner Nimish Shah speaks with Jason Fenton, managing director and head of health care capital markets at Cowen, to discuss the explosion of activity in the biotech IPO market this year. Fenton dives into the pros and cons of a virtual IPO process and shares best practices for companies looking to go public. Shah and Fenton outline some of the important factors to consider HERE COMES DIGITAL SPORTS COLLECTIBLES* *on a blockchain! Dapper Labs, in partnership with the NBA and the NBPA has launched the beta of their NBA TopShot crypto-collectible game. The first part of the experience allows consumers to buy packs of compelling NBA game moments. Users buy packs and try to complete various collections, build their teams and showcases, and starttrading with
INCENTIVES AND INFORMATION DRIVE HEALTH CARE INNOVATION This article first appeared in statnews.com. It is co-authored with Bryan Roberts. Health care in America often feels like it moves at a glacial pace, if that fast. Case in point: fax machines remain indispensable as a way of transferring information. On a larger scale, the U.S. health care system still struggles with readmissions, medication adherence, chronicNIMISH SHAH
Nimish originally joined Venrock in 2013 and has been investing in public and private healthcare companies since 2010. He works predominantly on Venrock’s public and cross-over biotech funds. He is currently a Board Director for InstilBio and Board Observer for LianBio. He previously served as a Board Observer for Biohaven Pharmaceuticals and Viridian Therapeutics. NimishMARIANA MIHALUSOVA
Mariana Mihalusova focuses on biotech and pharmaceutical investments. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to lifecycle management. Prior to joining Venrock, Mariana was an executive at Celgene Corporation (Research & Early Development), where she led the global development strategies for over aETHAN BATRASKI
Ethan is a Partner based in our Palo Alto office where he invests across sectors, with a particular focus on hard engineering problems such as developer tools & infrastructure, open source software, space, and emerging compute. He led the investments and serve as Board Member at Astranis, ABL Space, Astronomer, Atom Computing, Skyryse, and a TONY EVNIN - VENROCK Tony joined Venrock in 1974 and built the firm’s healthcare franchise, helping to shape the modern biotechnology industry. He currently serves on the Board of Directors of two public companies, AVEO Pharmaceuticals (NASDAQ: AVEO) and Infinity Pharmaceuticals (NASDAQ: INFI). Past investments include Acceleron (NASDAQ: XLRN), Celladon (NASDAQ: CLDN), Centocor (IPO/ acquired by Johnson* Portfolio
* Team
* Insights
* News
* About
* Careers
* Contact
* LP Login
*
* About
* Team
* Portfolio
* Insights
* News
* Careers
* Contact
* LP Login
*
Search
GENERAL RESULTS
VENROCK IN THE NEWS
Search
Cancel
GENERAL RESULTS
VENROCK IN THE NEWS
Search
GENERAL RESULTS
VENROCK IN THE NEWS
* About
* Team
* Portfolio
* Insights
* News
* Careers
* Contact
* LP Login
*
*
*
*
*
*
*
*
1 WEEK - 2 IPOS
CONGRATULATIONS
10X GENOMICS & CLOUDFLARE “VENROCK'S GUIDANCE IN THE EARLY DAYS OF CLOUDFLARE WAS A GREAT RESOURCE. THEY HAVE BEEN A PARTNER EVER SINCE.” Matthew Prince, Michelle Zatlyn andLee Holloway
CloudFlare
CANDID CONVERSATIONS ABOUT ENTREPRENEURSHIP Available on iTunes, SoundCloud and StitcherListen here
“OUR PARTNERS ARE AN EXTENSION OF OUR COMPANY, SO WE CHOOSE THEMCAREFULLY.”
Tony Fadell and Matt RogersNest
“THERE WAS NEVER ANY QUESTION ABOUT WHO WE WANTED AS OUR DEVOTED CO-FOUNDERS. AND THEY HAVE OUTPERFORMED ON EVERY DIMENSION.”Ed and Todd Park
Devoted Health
“I APPRECIATE VENROCK'S DRIVE TO WIN. THE FIRM HAS BEEN A PIONEER ACROSS MANY SECTORS AND THEIR CONTINUED FOCUS ON NOVEL APPROACHES TO MASSIVE MARKETS HAS MADE THEM GREAT.”Michael Dubin
Dollar Shave Club
“VENROCK HAS PASSION FOR SOLVING BIG PROBLEMS, RESPECT FOR ENTREPRENEURS, AND DEEP EMPATHY FOR THE PROCESS OF COMPANY BUILDING. THEY ARE NOT JUST OUR INVESTORS, THEY ARE OUR PARTNERS EVERY STEP OFTHE WAY.”
Nathan Gunn, Erin Palm, Karthik Rajan, and Punit SoniSuki
BUILD THE FUTURE
Venrock partners with entrepreneurs to achieve what others believe isimpossible.
*
*
*
*
*
*
WE INVEST IN TECHNOLOGY * Intelligent Enterprise & AI * Security & Infrastructure* Fintech
* Healthcare IT
* Defense & Aerospace * Robotics & Autonomy* Consumer
*
*
*
*
*
*
*
INTELLIGENT ENTERPRISE & AI AI is making software radically smarter, unlocking the value of unstructured data and enabling predictive capabilities to solve business problems in fundamentally new ways while requiring far less effort from users. The opportunity for value creation is more profound than even the shift from on-premise to Cloud.* View Portfolio
*
*
*
*
SECURITY & INFRASTRUCTURE Rapidly evolving enterprise infrastructure is accelerating hybrid cloud architecture and software development processes. A lack of sufficiently skilled workers for modernizing infrastructure and thwarting adversaries is threatening these changes and impacting how software is built, infrastructure is managed, and threats aremitigated.
* View Portfolio
*
*
*
*
FINTECH
Financial services have traditionally been delivered through massive brick and mortar networks with armies of workers and paper-intensive processes. Fintechs are removing middleman fees and opacity and enabling innovative new services. This increased efficiency and transparency yields radically new offerings at better prices.* View Portfolio
*
*
*
*
HEALTHCARE IT
The largest industry in the United States is being completely reconstructed as the twin tsunamis of incentives and information are brought to bear on an archaic system. Capitalism and information technology will create a dramatically more efficient healthcare system that provides better care.* View Portfolio
*
*
*
*
DEFENSE & AEROSPACE
Technology is changing the nature of national security, making the defense sector a more active early adopter of emerging technologies in AI, big data, cybersecurity, quantum computing and aerospace. The defense sector is also fueling a thriving space economy, which is revolutionizing critical services globally across communication, sensing, intelligence and connectivity.* View Portfolio
*
*
*
*
ROBOTICS & AUTONOMY
Demand for robots and autonomy across retail, material handling, defense and other markets is a $120B+ market growing 20% annually. We look for the best and brightest roboticists who obsess over solving hard customer problems.* View Portfolio
*
*
*
*
CONSUMER
The size of the global, internet-connected audience allows technology products to influence consumer behavior and lives on an unprecedented scale. We partner with founders obsessed with product and user experience who aim to fundamentally improve how we do things asconsumers.
* View Portfolio
*
*
*
*
WE INVEST IN HEALTHCARE * Therapeutics-Small Molecules * Therapeutics-Biologics* Medical Devices
* Diagnostics & New Technologies*
*
*
*
THERAPEUTICS-SMALL MOLECULES Leveraging novel biology and advances in chemistry, we seek out the most revolutionary small molecule therapeutics and platforms that have the opportunity to create large shareholder value and save millions oflives.
* View Portfolio
*
*
*
*
THERAPEUTICS-BIOLOGICS Drawing on decades of experience funding many of the leaders in biotechnology, we continue to invest in proteins and antibodies, as well as new therapeutic modalities, that target diseases unattainable or poorly treated by small molecules.* View Portfolio
*
*
*
*
MEDICAL DEVICES
Today, there are very interesting opportunities for novel, innovative device interventions to address complex diseases, as well as consumerappetites.
* View Portfolio
*
*
*
*
DIAGNOSTICS & NEW TECHNOLOGIES The industrialization of DNA sequencing over the last decade has created robust and cost efficient methods to diagnostics. The next decade will be even more fruitful, with novel technologies and content creating ever more powerful products to assist in the treatment ofpatients.
* View Portfolio
*
*
*
*
INSIGHTS
1.6.2021
by Bryan Roberts
Venrock 9
Venrock raised a new, $450 million pool of capital today to continue our mission to invest in early stage technology and healthcarebusinesses...
Full Article
9.28.2020
by Venrock
Venrock Adds Two New Investors: Mariana... Much has changed during the past six months, but our search for great talent hasn’t stopped. We are excited to welcome two Vice Presidentsto the...
Full Article
8.3.2020
by Ethan Batraski
Building A Responsive Future For Space... The backstory of our privileged investment into ABL Space Beginning of the new space economy We are at the beginning of a new era inthe...
Full Article
View Insights
*
*
*
1.6.2021
by Bryan Roberts
VENROCK 9
Venrock raised a new, $450 million pool of capital today to continue our mission to invest in early stage technology and healthcare businesses that are taking...Full Article
9.28.2020
by Venrock
VENROCK ADDS TWO NEW INVESTORS: MARIANA... Much has changed during the past six months, but our search for great talent hasn’t stopped. We are excited to welcome two Vice Presidentsto the firm,...
Full Article
8.3.2020
by Ethan Batraski
BUILDING A RESPONSIVE FUTURE FOR SPACE... The backstory of our privileged investment into ABL Space Beginning of the new space economy We are at the beginning of a new era in theSpace...
Full Article
NEWS
40 UNDER 40: RACQUEL BRACKEN9.2.2020
LYRA HEALTH HITS $1.1 BILLION VALUATION, AS CORONAVIRUS BOOSTS NEEDFOR TELETHERAPY
8.25.2020
FINTECH PERSONAL CAPITAL SELLS TO CANADIAN INSURER6.29.2020
View News
*
*
*
40 UNDER 40: RACQUEL BRACKEN9.2.2020
LYRA HEALTH HITS $1.1 BILLION VALUATION, AS CORONAVIRUS BOOSTS NEEDFOR TELETHERAPY
8.25.2020
FINTECH PERSONAL CAPITAL SELLS TO CANADIAN INSURER6.29.2020
INVESTMENT TEAM
BRIAN ASCHER
—
* Focus Areas SaaS & Enterprise, AI/ML, FinTech * Location Palo AltoHARRY BARBER
—
* Focus Areas Biotechnology* Location New York
ETHAN BATRASKI
—
* Focus Areas Developer, Open Source, Space * Location Palo AltoNICK BEIM
—
* Focus Areas Artificial Intelligence, Software, Fintech and Defense* Location New York
RACQUEL BRACKEN
—
* Focus Areas Biotechnology, Pharmaceuticals * Location Palo AltoPAUL DOSSA
—
* Focus Areas Biotechnology, Pharmaceuticals* Location New York
GALLAGHER (GALLY)
—
* Location Palo AltoANDREW GOTTESDIENER
—
* Focus Areas Biotechnology, Pharmaceuticals* Location New York
TODD GRAHAM
—
* Focus Areas Enterprise, Cybersecurity, Infrastructure * Location Palo AltoBOB KOCHER, MD
—
* Focus Areas Healthcare IT * Location Palo AltoBONG KOH
—
* Focus Areas Biotechnology* Location New York
MARIANA MIHALUSOVA
—
* Focus Areas Biotechnology, Pharmaceuticals * Location Palo AltoDAVID PAKMAN
—
* Focus Areas Consumer Products and Services, Robotics andAutomation, Crypto
* Location New York
JULIE PARK
—
* Focus Areas Consumer, Commerce, SMB & Creator Services * Location Palo AltoBRYAN ROBERTS
—
* Focus Areas Biotechnology, Diagnostics, Genomics, Healthcare IT,Medical Devices
* Location Palo AltoALEX ROSEN
—
* Focus Areas Biotechnology, Pharmaceuticals* Location New York
CAMILLE SAMUELS
—
* Focus Areas Biotechnology, Consumer Health, Medical Devices * Location Palo AltoNIMISH SHAH
—
* Focus Areas Biotechnology, Pharmaceuticals, Medtech, Tools* Location New York
MIKE TYRRELL
—
* Focus Areas Enterprise, Internet, Mobile* Location Boston
CONTACT
SILICON VALLEY
3340 Hillview Avenue, Palo Alto, California 94304—
Phone 650 561 9580
Fax 650 561 9180
—
View Map >
Keyboard shortcuts
Map DataMap data ©2021Terms of Use
Report a map error
Map data ©2021
NEW YORK
7 Bryant Park, 23rd FloorNew York, NY 10018
—
Phone 212.444.4100
Fax 212.444.4101
—
View Map >
Keyboard shortcuts
Map DataMap data ©2021 GoogleTerms of Use
Report a map error
Map data ©2021 GoogleBOSTON
34 Farnsworth St, 3rd Floor,Boston, MA 02210
—
Phone 617.995.2000
Fax 617.995.2001
—
View Map >
Keyboard shortcuts
Map DataMap data ©2021 GoogleTerms of Use
Report a map error
Map data ©2021 GoogleBack to top
Follow Us
Join our newsletter SubmitDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0